IBT
ALLO icon

International Biotechnology Trust’s Allogene Therapeutics ALLO Stock Holding History

International Biotechnology Trust’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$314K – 65
2022
Q4 		$314K Hold
50,000
– – 0.1% 61
2022
Q3 		$539K Buy
50,000
+49,430
+8,672% +$672K 0.17% 60
2022
Q2 		$50K Sell
570
-49,430
-99% -$439K 0.52% 42
2022
Q1 		$747K Hold
50,000
– – 0.17% 60
2021
Q4 		$747K Buy
+50,000
New +$882K 0.17% 63

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

International Biotechnology Trust's ALLO Position: Q1 2023 in Review

International Biotechnology Trust sold out of Allogene Therapeutics (ALLO) in Q1 2023, closing a stake of 50,000 shares — an estimated $314K sold.

International Biotechnology Trust first reported a position in ALLO in Q4 2021 and held it in 5 quarters. The position peaked at $747K in Q1 2022. 176 funds tracked by Wall St. Rank hold ALLO as of Q1 2023.

  • International Biotechnology Trust reported no remaining Allogene Therapeutics position as of Q1 2023 after selling out during the quarter.
  • International Biotechnology Trust sold 50,000 Allogene Therapeutics shares in Q1 2023, an estimated $314K.
  • International Biotechnology Trust first reported a position in Allogene Therapeutics in Q4 2021 and held it in 5 quarters.
  • International Biotechnology Trust's Allogene Therapeutics position peaked at $747K in Q1 2022.
  • 176 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2023.

Based on International Biotechnology Trust's 13F filing for Q1 2023, filed 18 May 2023.